BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 37366802)

  • 21. Interferon Lambda 4 Genotype Is Not Associated with Recurrence of Oral or Genital Herpes.
    Lang Kuhs KA; Kuniholm MH; Pfeiffer RM; Chen S; Desai S; Edlin BR; Peters MG; Plankey M; Sharp GB; Strickler HD; Villacres MC; Quinn TC; Gange SJ; Prokunina-Olsson L; Greenblatt RM; O'Brien TR
    PLoS One; 2015; 10(10):e0138827. PubMed ID: 26431156
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Polymorphism rs368234815 of interferon-λ4 gene and generation of antibodies to hepatitis B virus surface antigen in extracorporeal dialysis patients.
    Grzegorzewska AE; Świderska MK; Marcinkowski W; Mostowska A; Jagodziński PP
    Expert Rev Vaccines; 2020 Mar; 19(3):293-303. PubMed ID: 32228249
    [No Abstract]   [Full Text] [Related]  

  • 23. Interferon-λ4 (IFNL4) transcript expression in human liver tissue samples.
    Amanzada A; Kopp W; Spengler U; Ramadori G; Mihm S
    PLoS One; 2013; 8(12):e84026. PubMed ID: 24376784
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interferon lambda 4 gene polymorphisms as a predicting tool of response to hepatitis C virus genotype 4 patients treated with Sofosbuvir and Ribavirin.
    Sakr AA; Ahmed AE; Abd El-Maksoud MDE; Gamal A; El-Garem H; Ahmed OM
    Infect Genet Evol; 2020 Dec; 86():104606. PubMed ID: 33127459
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Presence of interferon-λ 4, male gender, absent/mild steatosis and low viral load augment antibody levels to hepatitis C virus.
    Waldenström J; Hellstrand K; Westin J; Nilsson S; Christensen P; Färkkilä M; Mørch K; Langeland N; Norkrans G; Lagging M
    Scand J Gastroenterol; 2021 Jul; 56(7):849-854. PubMed ID: 34078234
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hepatic IFNL4 expression is associated with non-response to interferon-based therapy through the regulation of basal interferon-stimulated gene expression in chronic hepatitis C patients.
    Murakawa M; Asahina Y; Kawai-Kitahata F; Nakagawa M; Nitta S; Otani S; Nagata H; Kaneko S; Asano Y; Tsunoda T; Miyoshi M; Itsui Y; Azuma S; Kakinuma S; Tanaka Y; Iijima S; Tsuchiya K; Izumi N; Tohda S; Watanabe M
    J Med Virol; 2017 Jul; 89(7):1241-1247. PubMed ID: 28036111
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Knockout IFNL4 Variant Is Associated With Protection From Sexually Transmitted HIV-1 Infection.
    Jaimes-Bernal C; Rallón N; Benito JM; Omar M; Gómez-Vidal MA; Márquez FJ; Sánchez-Arcas B; Trujillo M; Royo JL; Saulle I; Biasin M; Rivero-Juárez A; Caruz A
    J Infect Dis; 2019 Feb; 219(5):772-776. PubMed ID: 30289470
    [TBL] [Abstract][Full Text] [Related]  

  • 28.
    Rugwizangoga B; Andersson ME; Kabayiza JC; Nilsson MS; Ármannsdóttir B; Aurelius J; Nilsson S; Hellstrand K; Lindh M; Martner A
    Front Cell Infect Microbiol; 2019; 9():340. PubMed ID: 31637221
    [TBL] [Abstract][Full Text] [Related]  

  • 29. No Association of IFNL4 Genotype With Opportunistic Infections and Cancers Among Men With Human Immunodeficiency Virus 1 Infection.
    Fang MZ; Jackson SS; Pfeiffer RM; Kim EY; Chen S; Hussain SK; Jacobson LP; Martinson J; Prokunina-Olsson L; Thio CL; Duggal P; Wolinsky S; O'Brien TR
    Clin Infect Dis; 2023 Feb; 76(3):521-527. PubMed ID: 36573283
    [TBL] [Abstract][Full Text] [Related]  

  • 30. IFNL4 ss469415590 polymorphism contributes to treatment decisions in patients with chronic hepatitis C virus genotype 1b, but not 2a, infection.
    Wu R; Chi X; Wang X; Sun H; Lv J; Gao X; Yu G; Kong F; Xu H; Hua R; Jiang J; Sun B; Zhong J; Pan Y; Niu J
    Infect Genet Evol; 2016 Apr; 39():132-140. PubMed ID: 26820907
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Polymorphisms of interferon-λ4 and IL28B - effects on treatment response to interferon/ribavirin in patients with chronic hepatitis C.
    Stättermayer AF; Strassl R; Maieron A; Rutter K; Stauber R; Strasser M; Beinhardt S; Datz C; Scherzer TM; Steindl-Munda P; Gschwantler M; Trauner M; Hofer H; Ferenci P
    Aliment Pharmacol Ther; 2014 Jan; 39(1):104-11. PubMed ID: 24205831
    [TBL] [Abstract][Full Text] [Related]  

  • 32. IFNL4 rs368234815 polymorphism is associated with innate resistance to HIV-1 infection.
    Real LM; Herrero R; Rivero-Juárez A; Camacho Á; Macías J; Vic S; Soriano V; Viedma S; Guardiola JM; Fibla J; Rivero A; Pineda JA; Caruz A
    AIDS; 2015 Sep; 29(14):1895-7. PubMed ID: 26372394
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The IFN-λ4 Conundrum: When a Good Interferon Goes Bad.
    Onabajo OO; Muchmore B; Prokunina-Olsson L
    J Interferon Cytokine Res; 2019 Oct; 39(10):636-641. PubMed ID: 31241411
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The relationships between IFNL4 genotype, intrahepatic interferon-stimulated gene expression and interferon treatment response differs in HCV-1 compared with HCV-3.
    Holmes JA; Congiu M; Bonanzinga S; Sandhu MK; Kia YH; Bell SJ; Nguyen T; Iser DM; Visvanathan K; Sievert W; Bowden DS; Desmond PV; Thompson AJ
    Aliment Pharmacol Ther; 2015 Aug; 42(3):296-306. PubMed ID: 26032235
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hepatic Interferon-λ3 (IFNL3) Gene Expression Reveals Not to Be Attenuated in Non-Favorable IFNL3 rs4803217 or IFNL4 rs368234815 Minor Allele Carriers in Chronic Hepatitis C.
    Amanzada A; Reinhardt L; Fey D; Zeisberg EM; Mihm S
    PLoS One; 2015; 10(11):e0143783. PubMed ID: 26606750
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Performance and Value of IFN-Lambda3 and IFN-Lambda4 Genotyping in Patients with Chronic Hepatitis C (CHC) Genotype 2/3 in a Real World Setting.
    Wiegand SB; Heidrich B; Susser S; Rogalska-Taranta M; Petersen J; Böker KH; Grigorian N; Link R; Naumann U; John C; Lueth S; Malfertheiner P; Manns MP; Wedemeyer H; Sarrazin C; Cornberg M
    PLoS One; 2015; 10(12):e0145622. PubMed ID: 26699619
    [TBL] [Abstract][Full Text] [Related]  

  • 37. IFN-λ4 Attenuates Antiviral Responses by Enhancing Negative Regulation of IFN Signaling.
    Obajemu AA; Rao N; Dilley KA; Vargas JM; Sheikh F; Donnelly RP; Shabman RS; Meissner EG; Prokunina-Olsson L; Onabajo OO
    J Immunol; 2017 Dec; 199(11):3808-3820. PubMed ID: 29070670
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prevalence of Thymine--Adenine Dinucleotide Repeat, IL28B and IFNL4 in Thai Population and Correlation with Spontaneous Clearance and Treatment Outcome of Hepatitis C Infection.
    Thong VD; Wasitthankasem R; Tangkijvanich P; Vongpunsawad S; Poovorawan Y
    PLoS One; 2015; 10(5):e0125400. PubMed ID: 25938236
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association between variants in the interferon lambda 4 locus and substitutions in the hepatitis C virus non-structural protein 5A.
    Akamatsu S; Hayes CN; Ochi H; Uchida T; Kan H; Murakami E; Abe H; Tsuge M; Miki D; Akiyama R; Hiraga N; Imamura M; Aikata H; Kawaoka T; Kawakami Y; Chayama K
    J Hepatol; 2015 Sep; 63(3):554-63. PubMed ID: 25849245
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association of the IFNL4-ΔG Allele With Impaired Spontaneous Clearance of Hepatitis C Virus.
    Aka PV; Kuniholm MH; Pfeiffer RM; Wang AS; Tang W; Chen S; Astemborski J; Plankey M; Villacres MC; Peters MG; Desai S; Seaberg EC; Edlin BR; Strickler HD; Thomas DL; Prokunina-Olsson L; Sharp GB; O'Brien TR
    J Infect Dis; 2014 Feb; 209(3):350-4. PubMed ID: 23956438
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.